New Clinical Trial - Natreon’s PrimaVie® Shilajit Ingredient Showed Results of Improved Skin Health in Adult Women

10:00 EDT 10 Jul 2019 | PR Web

Natreon announces its PrimaVie® shilajit extract improves skin health in latest clinical trial.

NEW BRUNSWICK, N.J. (PRWEB) July 10, 2019

Natreon announces the results of the recently published randomized, double-blind, placebo controlled clinical study from Ohio State University Wexner Medical Center for PrimaVie®, its patented shilajit extract. PrimaVie® is an organic humic substance containing urolithins, fulvic acid, and micro minerals. Natreon is committed to continued scientific investment and research focused on the Beauty-From- Within and skin health categories. This marks the 10th clinical trial published by Natreon for its innovative biome optimized shilajit extract.

The present study aimed to evaluate the effects of oral shilajit supplementation on skin gene expression profile and micro perfusion in healthy adult females. The study design comprised of six total study visits, including the baseline visit (V1), and a final 14-week visit (V6) following shilajit supplementation (125 or 250mg bid). A skin biopsy of the left inner upper arm of each subject was collected at visits 2 and 6 for gene expression profiling using Affymetrix Clariom™ D Assay. Skin perfusion was determined by MATLAB processing of dermascopic images. Transcriptome data were normalized and subjected to statistical analysis. The differentially regulated genes were subjected to Ingenuity Pathway Analysis (IPAV R). The expression of the differentially regulated genes identified by IPAV R were
verified using real-time polymerase chain reaction (RT-PCR). Supplementation with shilajit for 14 weeks was not associated with any reported adverse effect within this period. At the higher dose (250mg bid), shilajit improved skin perfusion when compared to baseline or the placebo. Pathway analysis identified shilajit-inducible genes relevant to endothelial cell migration, growth of blood vessels, and ECM which were validated by quantitative RT-PCR analysis. This work demonstrates that oral shilajit supplementation induced genes relevant to endothelial cell migration, collagens and other extra-cellular matrix (ECM) proteins and growth of blood vessels, and improved skin micro perfusion in healthy adult women.

Dr. Sanni Raju, CEO of Natreon, stated, “This study adds to the growing clinical evidence for all the anti-aging benefits of PrimaVie® shilajit. Along with its earlier clinical studies, it’s proven that PrimaVie® shows highly significant upregulations of genes coding collagens (especially, COL1A1) and ECM proteins in skeletal muscle, such effect being synergistic with exercise. It also has shown to improve testosterone levels, mitochondrial function (increased ATP levels), endothelial function and cardiovascular health in healthy subjects.”


Click to read the full study.

For more information on PrimaVie® or Natreon’s full portfolio of ingredients, please email or visit

About PrimaVie:
PrimaVie® Biome Optimized Shilajit™ is sourced and purified from distinct biological ecosystems (biomes) and processed using sustainable green chemistry (water extraction), to provide optimal efficacy and bioactive diversity. This proprietary mineral extract has been studied in 10 randomized, double-blind, placebo-controlled human clinical trials. PrimaVie® is a powerful adaptogen standardized to achieve its proprietary composition consisting of urolithins (DBPs), fulvic acid and over 40 micro-minerals. PrimaVie® supports many health benefits such as boosting testosterone, strength, energy, and endurance levels, while also up-regulating the genes responsible for collagen synthesis. It has excellent applications in supplements, sports nutrition and healthy aging products. PrimaVie® is the only Non-GMO project verified, vegan, gluten free, and GRAS affirmed shilajit extract.

About Natreon:
Natreon is a leader in nutritional ingredient innovation, quality and research. Trusted by manufacturers for over 20 years, Natreon’s patented ingredients are derived from nature and founded on evidence-based Ayurveda. Committed to quality, its extracts are purified and standardized using proprietary process technology and controls that result in optimal levels of bioactive constituents. Natreon’s ingredients have been tested in multiple clinical studies (52 as of this date) and are GRAS-affirmed to ensure efficacy, safety and authenticity. Natreon brings storied knowledge and expertise in botanical cultivation and extraction, and its ingredients are sustainably sourced through an integrated supply chain to ensure quality and potency. Natreon has its global headquarters in New Jersey and a state-of-the-art R&D facility in Kolkata, India.

Dr. Sanni Raju, CEO & Chairman or Bruce Brown, President
2-D Janine Place
New Brunswick, NJ 08901
Tel: 732-296-1080

For the original version on PRWeb visit:


More From BioPortfolio on "New Clinical Trial - Natreon’s PrimaVie® Shilajit Ingredient Showed Results of Improved Skin Health in Adult Women"

Quick Search


Relevant Topics

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...